BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15356467)

  • 1. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
    Migliorati CA; Birman EG; Cury AE
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antifungal drug susceptibility of Candida causing oropharyngeal candidiasis in HIV infected patients].
    Dieng Y; Faye-Niang MA; Ndour-Diop A; Sow PS; Dieng T; Soumare M; Bah IB; Faye O; Diop BM; Gaye O; Ndir O; Diallo S
    Dakar Med; 2001; 46(1):4-7. PubMed ID: 15773146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients.
    Chunchanur SK; Nadgir SD; Halesh LH; Patil BS; Kausar Y; Chandrasekhar MR
    Indian J Pathol Microbiol; 2009; 52(4):501-4. PubMed ID: 19805956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
    Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
    J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
    Maninder J; Usha A
    J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of candida isolates from denture-related stomatitis to antifungal agents in vitro.
    Dorocka-Bobkowska B; Konopka K
    Int J Prosthodont; 2007; 20(5):504-6. PubMed ID: 17944341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predisposing factors for oropharyngeal colonization of yeasts in human immunodeficiency virus-infected patients: a prospective cross-sectional study.
    Lin JN; Lin CC; Lai CH; Yang YL; Chen HT; Weng HC; Hsieh LY; Kuo YC; Lauderdale TL; Tseng FC; Lin HH; Lo HJ
    J Microbiol Immunol Infect; 2013 Apr; 46(2):129-35. PubMed ID: 22921200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
    Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral candidiasis of HIV-infected children undergoing sequential HIV therapies.
    Melo NR; Taguchi H; Culhari VP; Kamei K; Mikami Y; Smith SN; Vilela MS
    Med Mycol; 2009 Mar; 47(2):149-56. PubMed ID: 18651304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
    Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
    J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility.
    De Bernardis F; Tacconelli E; Mondello F; Cataldo A; Arancia S; Cauda R; Cassone A
    FEMS Immunol Med Microbiol; 2004 May; 41(1):27-34. PubMed ID: 15094164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
    Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
    Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and antifungal resistance profile of Candida spp. oral isolates from patients with type 1 and 2 diabetes mellitus.
    Bremenkamp RM; Caris AR; Jorge AO; Back-Brito GN; Mota AJ; Balducci I; Brighenti FL; Koga-Ito CY
    Arch Oral Biol; 2011 Jun; 56(6):549-55. PubMed ID: 21183157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple oral Candida infections in patients with Sjogren's syndrome -- prevalence and clinical and drug susceptibility profiles.
    Yan Z; Young AL; Hua H; Xu Y
    J Rheumatol; 2011 Nov; 38(11):2428-31. PubMed ID: 21844143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
    Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
    Jiang L; Yong X; Li R; Peng Y; Liu W; Qin Q; Zhang L; Liu Z; Liang H; Tao R
    J Oral Pathol Med; 2014 Oct; 43(9):696-703. PubMed ID: 24931443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
    Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
    Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
    Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
    Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.